Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? - PubMed (original) (raw)

Review

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Paul Rutgeerts et al. Gut. 2007 Apr.

Abstract

The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that the need for surgery is not decreasing in this population over the years. There is recent evidence that with immunosuppression and treatment with infliximab long-term healing of the bowel can be achieved and that this affects the outcome of both Crohn's disease and ulcerative colitis. We propose that future studies should focus on healing and disease course as primary outcome measures.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Similar articles

• Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
  Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x. Aliment Pharmacol Ther. 2006. PMID: 16441465 Review.
• Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
  Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Caprilli R, et al. Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
• Medical treatment of inflammatory bowel diseases.
  Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Curr Opin Gastroenterol. 2005 Jul;21(4):443-7. Curr Opin Gastroenterol. 2005. PMID: 15930985 Review.
• Mucosal healing with anti-TNF antibodies.
  Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Chevaux JB, et al. Digestion. 2012;86 Suppl 1:16-22. doi: 10.1159/000341957. Epub 2012 Oct 5. Digestion. 2012. PMID: 23051722 Review.
• [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
  Stange EF. Stange EF. Z Gastroenterol. 2002 Apr;40 Suppl 1:S90-S1. doi: 10.1055/s-2002-23620. Z Gastroenterol. 2002. PMID: 11930299 German.

Cited by

• Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis.
  Laterza L, Piscaglia AC, Bibbò S, Arena V, Brisigotti M, Fabbretti G, Stefanelli ML, Cesario V, Maresca R, Poscia A, Pugliese D, Gaetani E, Papa A, Cammarota G, Armuzzi A, Gasbarrini A, Scaldaferri F. Laterza L, et al. J Pers Med. 2024 May 10;14(5):505. doi: 10.3390/jpm14050505. J Pers Med. 2024. PMID: 38793087 Free PMC article.
• Contrast-Enhanced Endoscopic Ultrasound Detects Early Therapy Response Following Anti-TNF Therapy in Patients with Ulcerative Colitis.
  Ellrichmann M, Schulte B, Conrad CC, Schoch S, Bethge J, Seeger M, Huber R, Goeb M, Arlt A, Nikolaus S, Röcken C, Schreiber S. Ellrichmann M, et al. J Crohns Colitis. 2024 Aug 6;18(7):1012-1024. doi: 10.1093/ecco-jcc/jjae034. J Crohns Colitis. 2024. PMID: 38457414 Free PMC article.
• A Pro-Regenerative Supramolecular Prodrug Protects Against and Repairs Colon Damage in Experimental Colitis.
  DeFrates KG, Tong E, Cheng J, Heber-Katz E, Messersmith PB. DeFrates KG, et al. Adv Sci (Weinh). 2024 Apr;11(13):e2304716. doi: 10.1002/advs.202304716. Epub 2024 Jan 21. Adv Sci (Weinh). 2024. PMID: 38247203 Free PMC article.
• Emerging Issues in Gastroenterology and Hepatology.
  Bass NM, Feagan B. Bass NM, et al. Gastroenterol Hepatol (N Y). 2009 Aug;5(8 Suppl 17):3-20. Gastroenterol Hepatol (N Y). 2009. PMID: 37967447 Free PMC article. Review. No abstract available.
• Therapeutic Targets for Emerging Biologic Therapies in IBD.
  Hanauer SB, Plevy SE, Sands BE, Targan SR. Hanauer SB, et al. Gastroenterol Hepatol (N Y). 2009 Jul;5(7 Suppl 16):4-16. Gastroenterol Hepatol (N Y). 2009. PMID: 37967429 Free PMC article. No abstract available.

References

1. 1. Modigliani R, Mary J Y, Simon J F.et al Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 199098811–818. - PubMed
2. 1. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 199031325–328. - PMC - PubMed
3. 1. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo‐) colitis with azathioprine. Gastrointest Endosc 199950667–671. - PubMed
4. 1. Lemann M, Mary J Y, Colombel J F.et al A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology 20051281812–1818. - PubMed
5. 1. D'Haens G, Geboes K, Ponette E.et al Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 19971121475–1481. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central